(Cervical Cancer) Is Cemiplimab Effective? EMPOWER-Cervical 1 Phase 3 Trial Results
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- June 7, 2021
- 2 min read
The EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 Phase 3 clinical trial evaluated cemiplimab (anti-PD-1 antibody) versus investigator's choice of chemotherapy in patients with recurrent cervical cancer who had progressed on prior platinum-based therapy. Results were published in the New England Journal of Medicine.
Trial Design:
Patients with recurrent, metastatic, or persistent cervical cancer who had progressed on prior platinum-containing chemotherapy were randomized to receive either cemiplimab 350 mg IV every 3 weeks or investigator's choice of single-agent chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary endpoint was overall survival (OS).
Results:
- Median OS: Cemiplimab 12.0 months vs. chemotherapy 8.5 months
- Hazard ratio: 0.69 (31% reduction in death risk)
- The OS benefit was observed regardless of PD-L1 expression status
Conclusion: Based on the EMPOWER-Cervical 1 trial results, cemiplimab demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy in patients with recurrent cervical cancer following platinum-based therapy.
Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Please consult your healthcare provider for medical decisions.
Source: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9. N Engl J Med. 2021.
Cervical Cancer | Immunotherapy | Cemiplimab
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4